Over last decade, Ajanta Pharma has established itself in emerging markets, also known as RoW (Rest of the World) with presence in more than 50 countries spread across Africa, CIS, Middle East, Latin America and South East Asia in the branded generic space.

Our presence spreads across wide range of therapeutic segments such as Anti-Malarial, Anti-biotic, Cardiovascular, Dermatology, Orthopedic, Gastroenterology, General Health, Gynecology, Male Erectile Dysfunction (MED) and Pediatric and our brands enjoy leadership position in many of these segments.

We have significant presence in Anti-Malarial segment in entire Africa. We were the 1st generic company to secure WHO Pre-Qualification for Artemether 20mg + Lumefantrine 120mg Tablets and Artemether 20mg + Lumefantrine Dispersible Tablets. We also hold the WHO Pre-qualification for Artesunate + Amodiaquine 25mg+67.5mg; 50mg+135mg; and 100mg+270mg Tablets. We were amongst the 1st company to have introduced Artemether + Lumefantrine in higher strengths such as 40mg+240mg; 60mg+360mg & 80mg+480mg to give dosage convenience to the patients resulting in better patient compliance. We promote entire Artemether + Lumefantrine range of products under the brand name of “Artefan” and “Combisunate” in Africa and they are by far leading brand in the anti-malarial segment.

Our other key brands are Apdyl H (Herbal Cough Syrup), Aprazole (Omeprazole Caps), Fedate (Iron Syrup & Cap), Kamagra (Sildenafil Tablets), Melacare (Hydroquinone Mometasone combination cream), Pinkoo Gripe Water and Trimol (Paracetamol Combination) promoted in various countries across different continents.

Out of the 50 countries we operate in, Ajanta has ground presence through its field force in over 30 countries where we aggressively promote our brands taking them to leadership positions.

Recently, we have made an initiative to tap Veterinary market in overseas countries. With this objective, we have floated separate division named “Vetrium” to handle Veterinary products in International Markets. We have already received product registrations in various countries and our veterinary initiative is gaining grounds.

With the objective of building sustainable and scalable business model, we have been continuously filing product registration dossiers in different countries in various therapeutic segments. Currently, Ajanta holds product registrations of over 1,400 products and another 1,300 & above products are awaiting approvals in various countries. Besides gaining market share from existing products, new product launches which are awaiting approvals will ensure sustained growth in years to come.

Thus Ajanta continues making strong footprints in emerging markets.